NRx Pharmaceuticals Inc. (NRXP)
| Bid | 2.03 |
| Market Cap | 35.02M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -25.13M |
| EPS (ttm) | -2.36 |
| PE Ratio (ttm) | -0.88 |
| Forward PE | 1.34 |
| Analyst | Buy |
| Ask | 2.12 |
| Volume | 70,967 |
| Avg. Volume (20D) | 207,888 |
| Open | 2.11 |
| Previous Close | 2.12 |
| Day's Range | 2.04 - 2.13 |
| 52-Week Range | 1.10 - 6.01 |
| Beta | 1.41 |
About NRXP
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal...
Analyst Forecast
According to 5 analyst ratings, the average rating for NRXP stock is "Buy." The 12-month stock price forecast is $31, which is an increase of 1397.58% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
NRx Pharmaceuticals, Inc. (NRXP) Q4 2024 Earnings Call TranscriptNRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q4 2024 Earnings Conference Call March 17, 2025 8:30 AM ET Company Participants Matthew Duffy - Chief Business Officer Jonathan Javitt - Founder, Chairman and ...
